Medicare Enrolled
Dr. Stephen Vara, M.D.
Hematology · North Port, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Vara from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Vara? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Vara
Dr. Stephen Vara is a hematology in North Port, FL, with 18 years in practice. Based on federal Medicare data, Dr. Vara performed 236,731 Medicare services across 6,448 unique beneficiaries.
Between the years covered by Open Payments, Dr. Vara received a total of $3,193 from 41 pharmaceutical and/or device companies across 168 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Vara is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice▲ Top 15% volume in FL$ $3,193 industry payments
Medicare Practice Summary
Medicare Utilization ↗236,731
Medicare services
Top 15% in FL for hematology
6,448
Unique beneficiaries
$14
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~13,152 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron sucrose injection (Venofer) | 41,000 | $0 | $5 |
| Iron infusion (Feraheme) | 26,520 | $0 | $4 |
| Pembrolizumab injection (Keytruda) | 21,000 | $43 | $137 |
| Anti-nausea injection (aprepitant) | 19,890 | $1 | $5 |
| Filgrastim injection (Zarxio) for white blood cells | 15,540 | $0 | $2 |
| Nivolumab injection (Opdivo) | 11,660 | $24 | $72 |
| Paclitaxel chemotherapy injection | 9,802 | $0 | $2 |
| Denosumab injection (Prolia/Xgeva) | 9,300 | $19 | $51 |
| Oxaliplatin chemotherapy injection | 9,250 | $0 | $12 |
| Injection, mepolizumab, 1 mg | 7,500 | $23 | $72 |
| Daratumumab injection (Darzalex) | 7,020 | $38 | $110 |
| Injection, atezolizumab, 10 mg | 5,556 | $64 | $196 |
| Epoetin alfa injection (Procrit) for anemia | 5,432 | $6 | $23 |
| Injection, durvalumab, 10 mg | 5,288 | $62 | $191 |
| Contrast dye for imaging (iodine-based) | 4,661 | $0 | $1 |
| Immune globulin infusion (Gammagard) | 4,118 | $36 | $108 |
| Azacitidine chemotherapy injection | 3,400 | $0 | $4 |
| Injection, eflapegrastim-xnst, 0.1 mg | 3,300 | $26 | $116 |
| Dexamethasone injection (steroid) | 3,208 | $0 | $3 |
| Complete blood count (CBC) with differential | 2,610 | $8 | $29 |
| Blood draw (venipuncture) | 2,522 | $8 | $9 |
| Anti-nausea injection (Aloxi/palonosetron) | 2,010 | $1 | $28 |
| Injection, bortezomib, 0.1 mg | 1,610 | $5 | $113 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 1,583 | $22 | $185 |
| Anti-nausea injection (ondansetron/Zofran) | 1,220 | $0 | $9 |
| Injection of additional new drug or substance into vein | 1,116 | $12 | $61 |
| Office visit, established patient (30-39 min) | 933 | $96 | $339 |
| Drug injection, under skin or into muscle | 872 | $10 | $69 |
| Injection, leucovorin calcium, per 50 mg | 817 | $3 | $12 |
| Injection, fluorouracil, 500 mg | 657 | $2 | $7 |
| Administration of chemotherapy into vein, 1 hour or less | 624 | $96 | $378 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 597 | $3 | $205 |
| Injection, carboplatin, 50 mg | 484 | $2 | $41 |
| Office visit, established patient (20-29 min) | 441 | $65 | $239 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 434 | $47 | $189 |
| Injection, cisplatin, powder or solution, 10 mg | 373 | $2 | $13 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 335 | $1 | $6 |
| Injection, potassium chloride, per 2 meq | 320 | $0 | $4 |
| Infusion, normal saline solution , 1000 cc | 282 | $2 | $7 |
| Injection, diphenhydramine hcl, up to 50 mg | 258 | $1 | $3 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 251 | $16 | $59 |
| Infusion into a vein for hydration, each additional hour | 232 | $10 | $42 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 224 | $15 | $56 |
| Injection, magnesium sulfate, per 500 mg | 213 | $1 | $2 |
| Administration of chemotherapy into vein, each additional hour | 208 | $21 | $79 |
| Office visit, established patient, complex (40-54 min) | 161 | $138 | $474 |
| Administration of additional new drug or substance into vein, 1 hour or less | 154 | $48 | $178 |
| Red blood count, automated test | 141 | $4 | $10 |
| Infusion into a vein for hydration, 31-60 minutes | 139 | $24 | $156 |
| Injection, zoledronic acid, 1 mg | 132 | $7 | $69 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 125 | $3 | $11 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 106 | $53 | $206 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 105 | $22 | $84 |
| Injection of drug or substance into vein | 99 | $28 | $156 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 80 | $122 | $637 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 70 | $4 | $15 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 64 | $24 | $89 |
| New patient office visit (45-59 min) | 62 | $119 | $453 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 59 | $1 | $7 |
| Administration of additional new drug or substance into vein using push technique | 57 | $42 | $170 |
| Initial hospital admission, high complexity | 56 | $135 | $556 |
| Ct scan of chest with contrast | 50 | $58 | $344 |
| New patient office visit (30-44 min) | 50 | $69 | $298 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 49 | $132 | $562 |
| Prothrombin time test (blood clotting) | 47 | $4 | $15 |
| Automated urinalysis | 38 | $2 | $8 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 37 | $15 | $56 |
| CT scan of abdomen and pelvis with contrast | 34 | $174 | $550 |
| Drawing of blood for a medical problem | 33 | $65 | $277 |
| New patient office visit, complex (60-74 min) | 32 | $173 | $585 |
| Hospital follow-up visit, moderate complexity | 23 | $63 | $197 |
| Transitional care management services for problem of at least moderate complexity | 16 | $158 | $533 |
| Transitional care management services for problem of high complexity | 15 | $203 | $722 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 14 | $401 | $680 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 12 | $1,098 | $3,706 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
13.6% high complexity
83.1% medium
3.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$3,193
Total received (2018-2024)
Avg $532/year across 6 years
Bottom 32% in FL for hematology
41
Companies
168
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,133 (98.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$60 (1.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$755
2023$703
2022$1,283
2021$203
2019$53
2018$195
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$306
PFIZER INC.
$297
Janssen Biotech, Inc.
$233
Daiichi Sankyo Inc.
$233
Genentech USA, Inc.
$231
Celgene Corporation
$194
Merck Sharp & Dohme LLC
$192
Novartis Pharmaceuticals Corporation
$191
Gilead Sciences, Inc.
$172
Seagen Inc.
$149
ARRAY BIOPHARMA INC
$110
Exelixis Inc.
$106
Takeda Pharmaceuticals U.S.A., Inc.
$49
Myovant Sciences Inc.
$48
JAZZ PHARMACEUTICALS INC.
$48
Incyte Corporation
$43
ABBVIE INC.
$42
AbbVie Inc.
$40
Regeneron Healthcare Solutions, Inc.
$36
ADC Therapeutics America, Inc.
$35
Merck Sharp & Dohme Corporation
$33
PharmaEssentia USA Corporation
$33
Amgen Inc.
$26
BeiGene USA, Inc.
$25
Rigel Pharmaceuticals, Inc.
$25
Telix Pharmaceuticals
$25
Eisai Inc.
$23
GENZYME CORPORATION
$22
GE HealthCare
$22
Deciphera Pharmaceuticals Inc.
$22
Kite Pharma, Inc.
$22
AstraZeneca Pharmaceuticals LP
$17
MorphoSys, US Inc.
$17
Karyopharm Therapeutics Inc.
$17
AbbVie, Inc.
$17
Seattle Genetics, Inc.
$17
Janssen Pharmaceuticals, Inc
$17
Apellis Pharmaceuticals, Inc.
$16
EISAI INC.
$16
Lilly USA, LLC
$14
Astellas Pharma US Inc
$12
Top 3 companies account for 26.2% of total payments
Associated products mentioned in payments ›
ADCETRIS · Alecensa · Avastin · BAVENCIO · BESREMI · BOSULIF · BRAFTOVI · BRUKINSA · CABOMETYX · CALQUENCE · Cabometyx · Columvi · DARZALEX · ENHERTU · ENJAYMO · ERLEADA · Empaveli · Enhertu · FRUZAQLA · GAZYVA · IBRANCE · ILLUCCIX · IMBRUVICA · JAKAFI · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LORBRENA · Lenvima · MONJUVI · MYLOTARG · NINLARO · Nplate · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · PADCEV · PEMAZYRE · PLUVICTO · Perjeta · Pomalyst · QINLOCK · REBLOZYL · TECVAYLI · TIVDAK · TUKYSA · Tavalisse · Trodelvy · VENCLEXTA · VERZENIO · Venclexta · XALKORI · XARELTO · XPOVIO · XTANDI · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (98%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $1 per 100 Medicare services performed
Geographic Context
Hematologys within 10 mi
12
Per 100K population
2.7
County median income
$80,633
Nearest hospital
Adventhealth Port Charlotte
8.4 mi
8.4 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Vara is a mixed practice specialist, with above-average Medicare volume (top 15% in FL), and low-engagement industry engagement, with 18 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Vara experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Vara performed 41,000 iron sucrose injection (venofer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Vara receive payments from pharmaceutical companies?
Yes. Dr. Vara received a total of $3,193 from 41 companies across 168 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Vara's costs compare to other hematologys in North Port?
Dr. Vara's average Medicare payment per service is $14. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Vara) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematologys in North Port
Browse hematologys in North Port ranked by procedure volume and transparency data.
Highest volume
Top Hematologys in FL
Hematologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematologys in FL
Which FL hematologys receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology